Early detection of COPD patients in GOLD 0 population: an observational non-interventional cohort study - MARKO study

Žarko Vrbica, Marina Labor, Ivan Gudelj, Slavica Labor, Iva Jurić, Davor Plavec, MARKO study group, Žarko Vrbica, Marina Labor, Ivan Gudelj, Slavica Labor, Iva Jurić, Davor Plavec, MARKO study group

Abstract

Background: Main risk factor for the development of chronic obstructive pulmonary disease (COPD) is smoking, although only less than 1/3 of smokers develop clinically manifest COPD. COPD's progressive nature with high disability and mortality makes it plausible to detect it as early as possible thus allowing for an early intervention. The only tool for an early diagnosis that could be used on the global scale is spirometry, even though symptoms and deprivation of health related quality of life (HRQoL) precede relevant spirometric changes. Existing HRQoL questionnaires are too complicated or not developed for an early detection of COPD. The aim of our study was to develop a new simple HRQoL tool that will allow (alone or in combination with other markers) early detection of patients with COPD.

Methods: A multicenter prospective cohort study recruiting 500 subjects at risk for COPD (smokers/ex-smokers ≥20 pack-years, 40-65 years, both sexes, with no prior diagnosis of COPD) will be carried out in two phases: (1) cross-sectional - development and validation of a new questionnaire; and (2) prospective - follow-up of a cohort of patients at risk for COPD. Subjects were recruited by 25 GPs and assessed for COPD by dedicated pulmonologists in 7 hospital centers using a predefined protocol: HRQoL, history, physical, blood sampling, exhaled breath temperature (EBT), lung function, 6-min walk test (6MWT). Patients without COPD and those in GOLD stage 1 at initial assessment will be reassessed for disease progression by the same pulmonologist after 2 and 5 years.

Discussion: This is one of the first cohort studies attempting to establish the incidence of COPD in the pre-symptomatic stage before significant end organ damage. We intend to assess the validity, predictability and discriminative power ('healthy' smokers vs. pre-symptomatic phase in newly developed COPD) of newly developed HRQoL tool alone or in combination with other markers; EBT, lung function, 6MWT, genomics, transcriptomics, proteomics). We expect that the results of this study can improve our understanding of the development of COPD, identify some new underlying pathophysiological pathways, and offer to sensitive smokers/ex-smokers new preventive and early intervention measures thus improving the management of COPD.

Trial registration: Clinicaltrial.gov NCT01550679 retrospectively registered February 28, 2012.

Keywords: Biological markers; Chronic obstructive pulmonary disease (COPD); Cigarette smoking; Disease susceptibility; Early diagnosis.

Figures

Fig. 1
Fig. 1
Flow chart of subjects through the MARKO study

References

    1. Kim W, Ling SH, Coxson HO, English JC, Yee J, Levy RD, et al. The association between small airway obstruction and emphysema phenotypes in COPD. Chest. 2007;131:1372–8. doi: 10.1378/chest.06-2194.
    1. Miravitlles M, Anzueto A. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT® studies. Int J Chron Obstruct Pulmon Dis. 2009;4:185–201.
    1. Greulich T, Koczulla R, Vogelmeier C, Bals R. Chronic obstructive pulmonary disease (COPD) as a systemic disease. Dtsch Med Wochenschr. 2009;134:1231–5. doi: 10.1055/s-0029-1222594.
    1. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59. doi: 10.1186/1465-9921-10-59.
    1. Antoniu SA. Descriptors of dyspnea in obstructive lung diseases. Multidiscip Respir Med. 2010;30:216–9. doi: 10.1186/2049-6958-5-3-216.
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2015. Available from: . Accessed 15 May 2015.
    1. Nardini S, Annesi-Maesano I, Del Donno M, Delucchi M, Bettoncelli G, Lamberti V, et al. The AIMAR recommendations for early diagnosis of chronic obstructive respiratory disease based on WHO/GARD model. Multidiscip Respir Med. 2014;9:46. doi: 10.1186/2049-6958-9-46.
    1. Wain LV, Shrine N, Miller S, Jackson VE, Ntalla I, Soler Artigas M, et al. Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. Lancet Respir Med. 2015;3:769–81. doi: 10.1016/S2213-2600(15)00283-0.
    1. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42:773–8. doi: 10.1136/thx.42.10.773.
    1. Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med. 1991;85(Suppl B:25–31):33–7.
    1. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation - the St George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–7. doi: 10.1164/ajrccm/145.6.1321.
    1. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003;1:13. doi: 10.1186/1477-7525-1-13.
    1. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline LN. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648–54. doi: 10.1183/09031936.00102509.
    1. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. and the ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3–95 years age range: the Global Lung Function 2012 equations. Eur Respir J. 2012;40:1324–43. doi: 10.1183/09031936.00080312.
    1. Oostveen E, MacLeod D, Lorino H, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003;22:1026–41. doi: 10.1183/09031936.03.00089403.
    1. Vogel J, Smidt U. Impulse Oscillometry. Analysis of lung mechanics in general practice and the clinic, epidemiological and experimental research. Frankfurt am Main: pmi Verlagsgruppe GmbH. 1994.
    1. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26:511–22. doi: 10.1183/09031936.05.00035005.
    1. Stocks J, Godfrey S, Beardsmore C, et al. Plethysmografic measurements of lung volume and airway resistance. Eur Respir J. 2001;17:302–12. doi: 10.1183/09031936.01.17203020.
    1. Roca J, Rodriguez-Roisin R, Cobo E, et al. Single-breath carbon monoxide diffusing capacity prediction equations from a Mediterranean population. Am Rev Respir Dis. 1990;141:1026–32. doi: 10.1164/ajrccm/141.4_Pt_1.1026.
    1. Popov TA, Dunev S, Kralimarkova TZ, Kraeva S, DuBuske LM. Evaluation of a simple, potentially individual device for exhaled breath temperature measurement. Respir Med. 2007;101:2044–50. doi: 10.1016/j.rmed.2007.06.005.
    1. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7. doi: 10.1164/ajrccm.166.1.at1102.
    1. Troosters T, Gosselink R, Decramer M. Six minute walk distance in healthy elderly subjects. Eur Respir J. 1999;14:270–4. doi: 10.1034/j.1399-3003.1999.14b06.x.
    1. Quanjer PH, Brazzale DJ, Boros PW, Pretto JJ. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046–54. doi: 10.1183/09031936.00195512.
    1. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS Task Force: ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319–38. doi: 10.1183/09031936.05.00034805.
    1. Lam DC, Hui CK, Ip MS. Issues in pulmonary function testing for the screening and diagnosis of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2012;18:104–11. doi: 10.1097/MCP.0b013e32834feae7.
    1. Haroon S, Jordan R, Takwoingi Y, Adab P. Diagnostic accuracy of screening tests for COPD: a systematic review and meta-analysis. BMJ Open. 2015;5:e008133. doi: 10.1136/bmjopen-2015-008133.
    1. Labor M, Vrbica Ž, Gudelj I, Labor S, Plavec D. Diagnostic accuracy of a pocket screening spirometer in diagnosing chronic obstructive pulmonary disease in general practice: a cross sectional validation study using tertiary care as a reference. BMC Fam Pract. 2016;17:112. doi: 10.1186/s12875-016-0518-8.
    1. Csikesz NG, Gartman EJ. New developments in the assessment of COPD: early diagnosis is key. Int J Chron Obstruct Pulmon Dis. 2014;9:277–86.
    1. Elbehairy AF, Webb KA, Neder JA, O’Donnell DE. Should mild COPD be treated? Evidence for early pharmacological intervention. Drugs. 2013;73:1991–2001. doi: 10.1007/s40265-013-0145-9.
    1. Li X, Zhou Y, Chen S, Zheng J, Zhong N, Ran P. Early intervention with tiotropium in Chinese patients with GOLD stages I-II chronic obstructive pulmonary disease (Tie-COPD): study protocol for a multicentre, double-blinded, randomised, controlled trial. BMJ Open. 2014;4:e003991. doi: 10.1136/bmjopen-2013-003991.
    1. Vrbica Ž, Labor M, Košćec Đuknić A, Radošević-Vidaček B, Gudelj I, Labor S, Jurić I, Calverley PM, Plavec D. Development and the initial validation of a new self-administered questionnaire for an early detection of health status changes in smokers at risk for chronic obstructive pulmonary disease (MARKO questionnaire) Croat Med J. 2016;57:425–33. doi: 10.3325/cmj.2016.57.425.
    1. Carpagnano GE, Ruggieri C, Scioscia G, Storto MM, Zoppo L, Foschino-Barbaro MP. Is the Exhaled Breath Temperature Sensitive to Cigarette Smoking? COPD. 2016;13:642–6. doi: 10.3109/15412555.2016.1143458.
    1. Labor M, Vrbica Ž, Gudelj I, Labor S, Jurić I, Plavec D. Exhaled Breath Temperature as a Novel Marker of Future Development of COPD: Results of a Follow-Up Study in Smokers. COPD. 2016;13:741–9. doi: 10.3109/15412555.2016.1164129.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться